Rhythm Pharmaceuticals, Inc. (1RV.F)
- Previous Close
51.00 - Open
53.50 - Bid 53.50 x --
- Ask 54.50 x --
- Day's Range
53.50 - 53.50 - 52 Week Range
32.20 - 62.50 - Volume
11 - Avg. Volume
0 - Market Cap (intraday)
3.406B - Beta (5Y Monthly) 2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-2.50 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
rhythmtx.comRecent News: 1RV.F
View MorePerformance Overview: 1RV.F
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1RV.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1RV.F
View MoreValuation Measures
Market Cap
3.41B
Enterprise Value
3.26B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.01
Price/Book (mrq)
201.08
Enterprise Value/Revenue
26.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-123.28%
Return on Assets (ttm)
-51.33%
Return on Equity (ttm)
-150.20%
Revenue (ttm)
136.86M
Net Income Avi to Common (ttm)
-174.02M
Diluted EPS (ttm)
-2.50
Balance Sheet and Cash Flow
Total Cash (mrq)
314.49M
Total Debt/Equity (mrq)
69.65%
Levered Free Cash Flow (ttm)
-96.71M